Mediar Therapeutics has completed enrollment in its Phase 2 WISPer trial, evaluating the first-in-class antibody MTX-463 in idiopathic pulmonary fibrosis patients, with 168 participants across multiple sites.
Why it matters. Patients with idiopathic pulmonary fibrosis may benefit from a new treatment approach targeting fibrosis progression.
A Phase 1 study was recently completed and a Phase 2 clinical study in patients with systemic sclerosis is now open (NCT07287670).
MTX-439 is a first-in-class human IgG1 antibody developed to neutralize the activity of SMOC2
Following completion of the Phase 2 study, Lilly will have the right to lead all further clinical development and commercialization of the program.
The current Phase 1 trial (NCT07473323) encompasses both healthy participants and adults with diabetic kidney disease
A Phase 2 study in patients with idiopathic pulmonary fibrosis is fully enrolled and ongoing (NCT06967805).
The global study enrolled 168 adults who were randomized to receive either MTX-463 or a matching placebo by intravenous infusion every four weeks for 24 weeks.
Mediar is also progressing novel fibro-inflammatory targets as part of a recently announced collaboration with Ono Pharmaceutical.
Mediar is conducting the Phase 2 WISPer study under a global licensing agreement with Eli Lilly and Company.
"Completing enrollment in the WISPer trial ahead of schedule brings us meaningful steps closer to understanding the potential of MTX-463 for people living with IPF," said Jeff Bornstein, MD, Chief Medical Officer of Mediar Therapeutics. "IPF remains a devastating disease with si…
BOSTON, Oct. 7, 2026 /PRNewswire/ -- Mediar Therapeutics, Inc., a clinical-stage biotechnology company pioneering first-in-class therapies to halt and reverse fibrosis, today announced completion of enrollment in its Phase 2 WISPer clinical study evaluating MTX-463 in patients w…
